In vitro and in vivo performance of a dual drug-eluting stent (DDES)
- PMID: 20189244
- DOI: 10.1016/j.biomaterials.2010.01.147
In vitro and in vivo performance of a dual drug-eluting stent (DDES)
Abstract
This study reports on a dual drug-eluting stent (DDES) that has an anti-proliferative and an anti-thrombotic in a biodegradable polymer-coated onto a cobalt-chromium stent. The DDES was prepared by spray coating the bare metal stent with a biodegradable polymer loaded with sirolimus and triflusal, to treat against restenosis and thrombosis, respectively. The 2-layered dual-drug coated stent was characterized in vitro for surface properties before and after expansion, as well as for possible delamination by cross-sectioning the stent in vitro. The in vitro anti-platelet behavior of the triflusal-loaded films was investigated by using dynamic platelet adhesion measurements. Additionally, the in vitro degradation and release study of the films and the stents w/single sirolimus and dual sirolimus-triflusal in different formulations were examined. Finally, in vivo studies (in a porcine carotid artery model) were performed for acute thrombosis, inflammation and restenosis at 30 days. The in vitro results show DDES can sustain release both anti-proliferation drug (sirolimus) and anti-thrombosis drug (triflusal), two drugs were controlled in different rates to effectively reduce thrombosis and proliferation at the same time. In vivo results show a significant reduction in restenosis with dual-drug eluting stent compared with the controls (a bare metal stent, a sirolimus coated and a pure polymer-coated stent). The reduction in restenosis with a dual sirolimus-triflusal eluting stent is associated with an inhibition of inflammation, especially thrombus formation, suggesting that such dual-drug eluting stents have a role to play for the treatment of coronary artery disease.
Copyright (c) 2010 Elsevier Ltd. All rights reserved.
Similar articles
-
The short-term effect on restenosis and thrombosis of a cobalt-chromium stent eluting two drugs in a porcine coronary artery model.J Interv Cardiol. 2009 Oct;22(5):466-78. doi: 10.1111/j.1540-8183.2009.00489.x. Epub 2009 Jul 13. J Interv Cardiol. 2009. PMID: 19627432
-
Drug-eluting stents.Arch Cardiol Mex. 2006 Jul-Sep;76(3):297-319. Arch Cardiol Mex. 2006. PMID: 17091802 Review.
-
The short-term effects on restenosis and thrombosis of echinomycin-eluting stents topcoated with a hydrophobic heparin-containing polymer.Biomaterials. 2007 Mar;28(8):1523-30. doi: 10.1016/j.biomaterials.2006.11.020. Epub 2006 Dec 8. Biomaterials. 2007. PMID: 17157376
-
Preclinical and early clinical experience with a biodegradable polymer-based, rapamycin-eluting, Indian drug-eluting coronary stent: the BIO-RAPID study.Indian Heart J. 2008 May-Jun;60(3):228-32. Indian Heart J. 2008. PMID: 19240312
-
Rapamycin analogs for stent-based local drug delivery. Everolimus- and tacrolimus-eluting stents.Herz. 2004 Mar;29(2):162-6. doi: 10.1007/s00059-004-2556-6. Herz. 2004. PMID: 15054588 Review.
Cited by
-
An Overview of In Vitro Drug Release Methods for Drug-Eluting Stents.Polymers (Basel). 2022 Jul 5;14(13):2751. doi: 10.3390/polym14132751. Polymers (Basel). 2022. PMID: 35808798 Free PMC article. Review.
-
Prevention of neointimal hyperplasia after coronary artery bypass graft via local delivery of sirolimus and rosuvastatin: network pharmacology and in vivo validation.J Transl Med. 2024 Feb 16;22(1):166. doi: 10.1186/s12967-024-04875-8. J Transl Med. 2024. PMID: 38365767 Free PMC article.
-
Coating Techniques and Release Kinetics of Drug-Eluting Stents.J Med Device. 2019 May 4;10(1):10.1115/1.4031718. doi: 10.1115/1.4031718. Epub 2015 Nov 5. J Med Device. 2019. PMID: 31156736 Free PMC article.
-
Accelerated in-vitro release testing methods for extended-release parenteral dosage forms.J Pharm Pharmacol. 2012 Jul;64(7):986-96. doi: 10.1111/j.2042-7158.2012.01482.x. Epub 2012 Mar 8. J Pharm Pharmacol. 2012. PMID: 22686344 Free PMC article. Review.
-
3D-printed Bioresorbable Stent Coated with Dipyridamole-Loaded Nanofiber for Restenosis Prevention and Endothelialization.Int J Bioprint. 2022 Feb 19;8(2):543. doi: 10.18063/ijb.v8i2.543. eCollection 2022. Int J Bioprint. 2022. PMID: 35669322 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical